SmithKline drops alliance with Vanguard on drugs

Article Abstract:

SmithKline Beecham PLC has abandoned a drug-development alliance with Vanguard Medica Ltd. of the UK, a biotechnology company. The two firms entered into a partnership five years ago to develop a potential migraine medicine whose generic name is frovatriptan. SmithKline, which discovered the drug, handed over clinical testing to Vanguard with a clause that enables it to regain marketing rights if development was a success. After Vanguard completed the clinical trials, SmithKline announced plans to file regulatory application for the drug in the US and Europe. However, SmithKline decided not to market the drug, said a company spokesman, as they have insufficient resources to commercialize the drug themselves.

Comment:

Biotechnology co's drug-development alliance with SmithKline Beecham PLC is abandoned by SmithKline

Strategic alliances, SmithKline Beecham PLC, Vanguard Medica Ltd.

---

Goldstein of SmithKline to head British biotech

Article Abstract:

British Biotech PLC selected 47-year-old pharmaceutical industry veteran Dr. Elliot Goldstein as the new CEO and succeed Keith McCullagh. McCullagh is stepping down from the firm's helm in the wake of difficulties in research programs and charges that sent the company stock declining. Goldstein will handle responsibilities of rebuilding the battered reputation of the firm with investors, but some analysts caution he may also attack costs more aggressively than his predecessor. Analysts added the new executive must still prove he can manage broad executive responsibilities and contracts with investors.

Comment:

Selects 47-year-old pharmaceutical industry veteran Dr Elliot Goldstein as the new CEO and succeed Keith McCullagh

Executive changes & profiles, British Biotech PLC

---

AstraZeneca arrives ahead of schedule; merged drugs company will be world no. 3

Article Abstract:

United Kingdom's pharmaceuticals giant Zeneca Group PLC and Sweden's Astra AB have completed their $37.7 billion merger deal on time. The new merged company AstraZeneca PLC is poised to be world's third largest pharmaceutical company.

Comment:

Zeneca Group PLC and Astra AB complete merger on time.

Asset sales & divestitures, Acquisitions & mergers, Sweden, Market share, Management, Pharmaceutical industry, Mergers, acquisitions and divestments, AstraZeneca PLC, Astra AB, Zeneca Group PLC

Similar abstracts:

• Abstracts: Competing a deal with military precision. The key to adding value in Scandinavian buyouts. From nothing to 70 million pounds sterling
• Abstracts: New crop: military may be left out of top leadership. Last refuge. Partners in dialogue
• Abstracts: Singapore Telecom faces a new world of competition. Good news amid the gloom. More licenses in Singapore
• Abstracts: Bjorn again and with Euro vision. Will to power. Desperately seeking value
• Abstracts: G-networks with multiple classes of signals and positive customers. On G-networks and resource allocation in multimedia systems

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.